Le Lézard
Classified in: Health
Subject: PER

Nomination Committee of Medivir appointed


STOCKHOLM, Oct. 28, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the nomination committee now has been appointed ahead of the Annual General Meeting in May 2022. 
According to an AGM resolution, the Nomination Committee 2021-2022 should consist of representatives of at least the three largest shareholders at the end of the third quarter of 2021 and the Chairman of the Board. 

Work on composing the Nomination Committee is now completed, and this year's Nomination Committee consists of: 
Karl Tobieson (Chairman), appointed by Linc AB
Jan Särlvik, appointed by Nordea Fonder
Anders Hallberg, appointed by HealthInvest Partners 
Uli Hacksell, Chairman of the Board, Medivir AB

The Annual General Meeting of Medivir will be held on Thursday May 5, 2022.

For further information, please contact:
Magnus Christensen, interim CEO and CFO
Phone: +46 (0)8 5468 3100
E-mail: [email protected]    

About Medivir

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects.  
Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/medivir/r/nomination-committee-of-medivir-appointed,c3442902

The following files are available for download:

https://mb.cision.com/Main/652/3442902/1488188.pdf

Press release (PDF)

SOURCE Medivir


These press releases may also interest you

at 01:24
Sedana Medical completes patient recruitment for INSPiRE-ICU 1 clinical trial in the US
Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 1 phase III clinical trial in the United States. Concurrently, the identical INSPiRE-ICU 2 trial is nearing completion, with 23 of 235...

at 01:17
Essity's Interim Report, Quarter 1, 2024
Quarter 1, 2024 - High profitability and strong cash flow Net sales decreased 4.1% to SEK 34,850m (36,352)Organic growth amounted to -4.0%, of which volume accounted for -1.8% and price/mix -2.2%. Excluding restructuring and exited contracts, volumes...

at 00:05
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:05
Few small SUVs excel in new IIHS front crash prevention test
The Insurance Institute for Highway Safety is updating its vehicle-to-vehicle front crash prevention test to address crashes that occur at higher speeds and those in which the struck vehicle is a motorcycle or large truck. Only one of the first 10...

at 00:00
Nutriessential expands globally to Oceania, Asia and the Gulf
Nutriessential.com recently announced its expansion into Oceania, Asia, and the Gulf. The company has been providing science-backed GMP-certified supplements in the US, Europe and Canada since 2005 and decided to expand owing to rising global demands...

24 avr 2024
Summit Clinical Research Statement on Co-Founder and Chairman Dr. Stephen Harrison
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.   During an illustrious 30-year...

More news about Health...


News published on and distributed by: